QCG
BMY.RT

Quadrant Capital Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Quadrant Capital Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-382
Closed – – 2513
2020
Q4 		$0 Buy
382
+369
+2,838% +$786 ﹤0.01% 2420
2020
Q3 		$0 Sell
13
-476
-97% -$1.36K ﹤0.01% 2380
2020
Q2 		$2K Hold
489
– – ﹤0.01% 1990
2020
Q1 		$2K Sell
489
-579
-54% -$1.91K ﹤0.01% 1933
2019
Q4 		$1K Buy
+1,068
New +$2.78K ﹤0.01% 2380

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Quadrant Capital Group's BMY.RT Position: Q1 2021 in Review

Quadrant Capital Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 382 shares.

Quadrant Capital Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Quadrant Capital Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 382 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Quadrant Capital Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Quadrant Capital Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Quadrant Capital Group's 13F filing for Q1 2021, filed 12 May 2021.